Savara's rare lung disease drug meets main goal in late-stage study (updated)
26/06/2024 11:58
(Adds details from the study)
June 26 (Reuters) - Savara SVRA.O on Wednesday said
its experimental drug,
molgramostim, met the main goal of a late-stage trial for
treating a rare lung disease characterized by a feeling of
breathlessness.
The drug developer's inhaled drug showed statistically
significant improvement in a measure called Diffusing Capacity
of the Lungs for Carbon Monoxide (DCLO) in patients compared to
placebo at week 24.
DCLO measures the lungs's ability to transfer gas from
inhaled air to red blood cells in pulmonary capillaries.
The trial tested molgramostim in treating adult patients
with Autoimmune Pulmonary Alveolar Proteinosis (aPAP).
(Reporting by Pratik Jain in Bengaluru; Editing by Tasim Zahid)
((Pratik.Jain@thomsonreuters.com;))